Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04402840

Enrollment

Registered

2020-05-27

Start date

2020-04-24

Completion date

2020-12-31

Last updated

2025-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome, COVID-19

Keywords

Acute Respiratory Distress Syndrome, COVID-19, Autonomic Nervous System, Stellate Ganglion

Brief summary

The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.

Detailed description

Primary Aim: • To determine safety of stellate ganglion block (SGB) in ARDS Secondary Aim: * To determine efficacy of SGB in slowing the progression of ARDS

Interventions

PROCEDUREStellate Ganglion Block

The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Subjects age 18 to 80 * Subjects with PCR documented diagnosis of COVID-19 ARDS requiring critical care and transfer to intensive care unit * Bilateral opacities consistent with pulmonary edema must be present and may be detected on CT or chest radiograph

Exclusion criteria

* Subjects with pre-existing cardiac failure * Hemodynamic Instability * Subject on Extracorporeal membrane oxygenation (ECMO) * Anatomical inability to do a stellate block

Design outcomes

Primary

Measure	Time frame	Description
Adverse events related to SGB	3 Months	Adverse events that can atleast unlikely be attributed to SGB
All Adverse events	3 Months	All adverse events related to COVID-19
Death	3 Months	Death due to any cause

Secondary

Measure	Time frame	Description
Assessment of respiratory/ pulmonary function	3 Months	Change from baseline clinical respiratory/pulmonary function as assessed by change in PF ratio
Radiographic criteria	3 Months	Change from last imaging data obtained prior to SGB procedure
Cardiac function	3 Months	Change from baseline clinical cardiac function as assessed by improvement in arrhythmia as measured by standard of care ECG ( rate, rhythm and / or any aberrant electro physiological changes)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026